EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

Amanda Nizam iD, Charles B Nguyen iD, Jinju Li, Emily C Zabor iD, Pavlos Msaouel iD, Cindy Y Jiang iD, Omar Alhalabi iD, Eugene Oh iD, Matthew P Davidsohn iD, Ilana B Epstein iD, Dimitra Rafailia Bakaloudi iD, Rafee Talukder iD und 27 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71284 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Amanda Nizam und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoconjugates, Urologic Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Enfortumab vedotin‐ejfv (EV), an antibody–drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real‐world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV‐related dermatologic toxicities, but survival implications remain unclear. This analysis assessed the safety of EV monotherapy and the impact of dermatologic and neurologic toxicities on efficacy outcomes in a multi‐institutional cohort. Materials and Methods UNITE is a multicenter, retrospective study across 16 US sites of patients with aUC treated with targeted agents, including EV. Primary endpoints were the incidence of EV treatment‐related adverse events (TRAEs, any grade) and TRAE‐related treatment modifications. Secondary endpoints included a comparison of ORR, progression‐free survival (PFS), and overall survival (OS) between patients with and without dermatologic toxicities and neuropathy. To reduce immortal time bias, Cox regression models incorporated TRAEs as time‐dependent covariates to adjust for EV treatment duration as well as Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, and liver metastases.

Results

Between 2018 and 2023, 485 patients with aUC received > 1 dose of EV monotherapy. Most (67%) received > 2 prior therapy lines. Any grade TRAEs occurred in 77%, most frequently neuropathy (36%) and dermatologic toxicities (27%); 57% required treatment modification and 21% discontinued EV, primarily due to neuropathy (9%) and fatigue (3%). Patients with dermatologic toxicities and neuropathy had higher ORR (56% vs. 42%; p = 0.007 and 64% vs. 35%; p < 0.0001, respectively). Neuropathy was independently associated with improved OS (HR 0.66; 95% CI 0.50–0.87; p = 0.002); dermatologic TRAEs were not associated with PFS or OS benefit.

Conclusions

EV safety outside clinical trials was consistent with prior reports, with no new signals. Treatment modifications were most often due to neuropathy, dermatologic toxicities, and fatigue. Both dermatologic toxicities and neuropathy correlated with higher ORR, but only neuropathy was independently associated with improved OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalImmunoconjugatesUrologic NeoplasmsCarcinoma, Transitional CellAntineoplastic Agents, ImmunologicalUrinary Bladder NeoplasmsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

adverse eventsantibody–drug conjugatesenfortumab vedotintreatment‐related toxicityurothelial carcinoma

Substanzen

enfortumab vedotinAntibodies, MonoclonalImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • Department of Hematology and Oncology, University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
  • Department of Biostatistics, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Amanda Nizam, Charles B Nguyen, Emily C Zabor, Pavlos Msaouel, Cindy Y Jiang, Omar Alhalabi, Eugene Oh, Matthew P Davidsohn, Ilana B Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder, Tanya Jindal, Amy K Taylor, Michael J Glover, Ali Raza Khaki, Bashar Abuqayas, Albert Jang, Jason R Brown, Arnab Basu, Mehmet A Bilen, Pedro C Barata, Yousef Zakharia, Matthew I Milowsky, Deepak Kilari, Christopher J Hoimes, Sumit A Shah, Hamid Emamekhoo, Nancy B Davis, Shilpa Gupta, Petros Grivas, Joaquim Bellmunt, Matthew T Campbell, Ajjai S Alva, Vadim S Koshkin

Förderung

  • NCI NIH HHS

Zitieren

APA

Nizam, A., Nguyen, C. B., Li, J., Zabor, E. C., Msaouel, P., Jiang, C. Y., Alhalabi, O., Oh, E., Davidsohn, M. P., Epstein, I. B., Bakaloudi, D. R., Talukder, R., Jindal, T., Taylor, A. K., Glover, M. J., Khaki, A. R., Lemke, E., Mabey, H., Abuqayas, B., …, & Koshkin, V. S. (2025). Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Medicine. https://doi.org/10.1002/cam4.71284

Vancouver

Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, et al. Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Medicine. 2025. doi:10.1002/cam4.71284

BibTeX
@article{Nizam2025,
  author = {Nizam, Amanda and Nguyen, Charles B and Li, Jinju and Zabor, Emily C and Msaouel, Pavlos and Jiang, Cindy Y and Alhalabi, Omar and Oh, Eugene and Davidsohn, Matthew P and Epstein, Ilana B and Bakaloudi, Dimitra Rafailia and Talukder, Rafee and Jindal, Tanya and Taylor, Amy K and Glover, Michael J and Khaki, Ali Raza and Lemke, Emily and Mabey, Hannah and Abuqayas, Bashar and Jang, Albert and Brown, Jason R and Evans, Sean T and Pywell, Cameron and Basu, Arnab and Bilen, Mehmet A and Barata, Pedro C and Zakharia, Yousef and Milowsky, Matthew I and Kilari, Deepak and Hoimes, Christopher J and Shah, Sumit A and Emamekhoo, Hamid and Davis, Nancy B and Gupta, Shilpa and Grivas, Petros and Bellmunt, Joaquim and Campbell, Matthew T and Alva, Ajjai S and Koshkin, Vadim S},
  title = {Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71284}
}
Kostenlos starten →